Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02091141
Title My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Genentech
Indications

Advanced Solid Tumor

biliary tract cancer

urinary bladder cancer

salivary gland cancer

Therapies

Erlotinib

Alectinib

Cobimetinib + Vemurafenib

Pertuzumab + Trastuzumab

Vismodegib

Atezolizumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST